Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed Aug 28, 2026 · 10-Q · 150 days after period end · 0001731122-26-001166
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$5.34M | -$11.20M | -$10.55M | -$13.11M |
| EPS Diluted | -$0.06 | -$0.13 | -$0.13 | -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed Aug 28, 2026 · 150 d after period end
